| Symbol | HRMY |
|---|---|
| Name | HARMONY BIOSCIENCES HOLDINGS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 630 W. GERMANTOWN PIKE,SUITE 215, PLYMOUTH MEETING, Pennsylvania, 19462, United States |
| Telephone | +1 484 539-9800 |
| Fax | — |
| — | |
| Website | https://www.harmonybiosciences.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001802665 |
| Description | Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The companys product WAKIX pitolisant is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy. Additional info from NASDAQ: |
📋 SANDIP KAPADIA (Ex-Officer) plans to sell 45K shares of HARMONY BIOSCIENCES HOLDINGS, INC. (at $31.51 each, total $1.4M) Filed: May 08, 2026 | ID: 004242
Read more(19% Negative) HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) Reports Q2 2026 Financial Results
Read moreHarmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
Read moreHarmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
Read moreHarmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting
Read moreZaeske Adam H. 🟡 adjusted position in 3.2K shares (1 derivative) of Harmony Biosciences Holdings, Inc. (HRMY) at $27.62 Transaction Date: Apr 07, 2026 | Filing ID: 000004
Read moreAnastasiou Peter 🟢 acquired 212.2K shares (1 derivative) of Harmony Biosciences Holdings, Inc. (HRMY) at $27.74 ($5.9M) Transaction Date: Apr 02, 2026 | Filing ID: 000002
Read moreIgnelzi Troy A. 🟢 acquired 17.7K shares (1 derivative) of Harmony Biosciences Holdings, Inc. (HRMY) at $27.74 Transaction Date: Apr 02, 2026 | Filing ID: 000003
Read more